Company identity
Company number 09033118
Company profile
UK company 09033118, incorporated on 9 May 2014.
Personalised surgical innovation | Orthoscape UK
Orthoscape offers cutting edge medical device design & additive manufacturing. We offer patient-specific surgical treatments with our main product, the Tailored Osteotomy Knee Alignment (TOKA) system.
Company number 09033118
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
CS01 | Transaction MzUyOTg3MDc0MWFkaXF6a2N4
Published 01 Jul 2026 14:54
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
13 Apr 2021 to 13 Apr 2022
Due to COVID-19, the majority of routine surgical procedures have been suspended. Lifting restrictions and returning to surgery, however, places a significant burden on the NHS. Further, demand for elective joint replacement surgery for osteoarthritis is set to double by 2030. Consequently, surgeons and patients need to interact in new ways to enable proc...
1 Oct 2020 to 30 Sep 2021
3D Metal Printing (3D-MP) develop solutions for public health improvements by continually innovating and improving our product range to deliver superior patient outcomes. We additively manufacture a range of custom-made medical devices and digital applications for 3D surgical planning. Additive manufacturing is an innovative technology that works by fusin...
1 Jun 2020 to 28 Feb 2021
3D Metal Printing Ltd. is a MedTech engineering company based at the University of Bath Innovation Centre. Our mission is to restore outstanding patient quality of life using custom-made treatments. We develop solutions for public health improvements by continually innovating and improving our product range to deliver superior patient outcomes. We additiv...
1 Apr 2017 to 28 Feb 2018
The lifetime risk of knee osteoarthiritis is estimated to be as high as 45% (most common muscoloskeletal disease in the world). The current main standard of care for end-stage knee OA is joint replacement, effective for older patients but incurs a high cost to the healthcare system. For younger patients (40 to 65 yrs.) the risk of knee replacement failure...